Combination inhibition of MET and EGFR has shown increased PFS in patients with NSCLC with MET overexpression, and targeting HGF/MET may help overcome resistance to EGFR or VEGFR inhibitors [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.